CAMCEVI 42 mg, suspension for injection with extended release syringe
Active ingredients: LEUPRORÉLINE, MÉSILATE DE LEUPRORÉLINE
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for injection with extended releasesyringesous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CAMCEVI 42 mg, suspension injectable à libération prolongée
- Pharmaceutical form
- suspension injectable à libération prolongée
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) copolymère de cyclooléfines (COC) avec aiguille(s) sécurisée(s)
- Marketing authorisation holder
- ACCORD HEALTHCARE (ESPAGNE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 26 Feb 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65867330CIP73025568CIP133400930255681Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LEUPRORÉLINEsuspension | 42 mg · une seringue préremplie | FT |
| MÉSILATE DE LEUPRORÉLINEsuspension | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.